Aggregation-prone peptides modulate activity of bovine interferon gamma released from naturally occurring protein nanoparticles.

[1]  M. A. Perillo,et al.  Superactive β-galactosidase inclusion bodies. , 2019, Colloids and surfaces. B, Biointerfaces.

[2]  N. Ferrer-Miralles,et al.  A new approach to obtain pure and active proteins from Lactococcus lactis protein aggregates , 2018, Scientific Reports.

[3]  M. Tutino,et al.  Getting value from the waste: recombinant production of a sweet protein by Lactococcus lactis grown on cheese whey , 2018, Microbial Cell Factories.

[4]  E. Vázquez,et al.  Release of targeted protein nanoparticles from functional bacterial amyloids: A death star‐like approach , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[5]  R. Khodarahmi,et al.  Enhancement of intrinsic fluorescence of human carbonic anhydrase II upon topiramate binding: Some evidence for drug-induced molecular contraction of the protein. , 2018, International journal of biological macromolecules.

[6]  Vera D. Jäger,et al.  Catalytically-active inclusion bodies-Carrier-free protein immobilizates for application in biotechnology and biomedicine. , 2017, Journal of biotechnology.

[7]  Esther Vázquez,et al.  Bacterial Inclusion Bodies: Discovering Their Better Half. , 2017, Trends in biochemical sciences.

[8]  Qing Dong,et al.  Conformational Characteristics of Rice Hexokinase OsHXK7 as a Moonlighting Protein involved in Sugar Signalling and Metabolism , 2017, The Protein Journal.

[9]  Guangpu Li,et al.  A simple method for recombinant protein purification using self-assembling peptide-tagged tobacco etch virus protease. , 2016, Protein expression and purification.

[10]  Daniel B. Roche,et al.  DisProt 7.0: a major update of the database of disordered proteins , 2016, Nucleic acids research.

[11]  E. Vázquez,et al.  Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs , 2016, Scientific Reports.

[12]  J. Veciana,et al.  Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. , 2016, Acta biomaterialia.

[13]  Sourav Bhattacharjee,et al.  DLS and zeta potential - What they are and what they are not? , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[14]  U. Rinas,et al.  Structural and functional features of self-assembling protein nanoparticles produced in endotoxin-free Escherichia coli , 2016, Microbial Cell Factories.

[15]  Esther Vázquez,et al.  Recombinant pharmaceuticals from microbial cells: a 2015 update , 2016, Microbial Cell Factories.

[16]  E. Redwan,et al.  Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives. , 2015, Journal of microbiology and biotechnology.

[17]  N. Ferrer-Miralles,et al.  A novel bio-functional material based on mammalian cell aggresomes , 2015, Applied Microbiology and Biotechnology.

[18]  Zoya Ignatova,et al.  Optimization of Translation Profiles Enhances Protein Expression and Solubility , 2015, PloS one.

[19]  J. Corchero,et al.  Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins , 2015, Microbial Cell Factories.

[20]  Vaibhav Upadhyay,et al.  Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process , 2015, Microbial Cell Factories.

[21]  A. Villaverde,et al.  Expanding the recombinant protein quality in Lactococcus lactis , 2014, Microbial Cell Factories.

[22]  S. Singh,et al.  Optimization of conditions for expression of recombinant interferon-γ in E.coli , 2014, Molecular Biology Reports.

[23]  Masaya Miyazaki,et al.  Refolding Techniques for Recovering Biologically Active Recombinant Proteins from Inclusion Bodies , 2014, Biomolecules.

[24]  T. Alves,et al.  Experimental design approach in recombinant protein expression: determining medium composition and induction conditions for expression of pneumolysin from Streptococcus pneumoniae in Escherichia coli and preliminary purification process , 2014, BMC Biotechnology.

[25]  Zhou Yu,et al.  Utilizing dynamic light scattering as a process analytical technology for protein folding and aggregation monitoring in vaccine manufacturing. , 2013, Journal of pharmaceutical sciences.

[26]  N. Ferrer-Miralles,et al.  Bacterial cell factories for recombinant protein production; expanding the catalogue , 2013, Microbial Cell Factories.

[27]  M. A. Perillo,et al.  β-galactosidase at the membrane-water interface: a case of an active enzyme with non-native conformation. , 2013, Colloids and surfaces. B, Biointerfaces.

[28]  E. Garcia-Fruitós.  Lactic acid bacteria: a promising alternative for recombinant protein production , 2012, Microbial Cell Factories.

[29]  T. Hünig.  The storm has cleared: lessons from the CD28 superagonist TGN1412 trial , 2012, Nature Reviews Immunology.

[30]  A. Panda,et al.  Kinetics of Inclusion Body Formation and Its Correlation with the Characteristics of Protein Aggregates in Escherichia coli , 2012, PloS one.

[31]  Zhanglin Lin,et al.  Small surfactant-like peptides can drive soluble proteins into active aggregates , 2012, Microbial Cell Factories.

[32]  R. Komel,et al.  Active Protein Aggregates Produced in Escherichia coli , 2011, International journal of molecular sciences.

[33]  Elena García-Fruitós,et al.  Inclusion bodies: a new concept , 2010, Microbial cell factories.

[34]  Peter Neubauer,et al.  Quality control of inclusion bodies in Escherichia coli , 2010, Microbial cell factories.

[35]  K. J. Mukherjee,et al.  Kinetic studies of recombinant human interferon-gamma expression in continuous cultures of E. coli , 2009, Journal of Industrial Microbiology & Biotechnology.

[36]  G. Schares,et al.  Indoleamine 2,3-Dioxygenase Is Involved in Defense against Neospora caninum in Human and Bovine Cells , 2009, Infection and Immunity.

[37]  A. Villaverde,et al.  Yield, solubility and conformational quality of soluble proteins are not simultaneously favored in recombinant Escherichia coli. , 2008, Biotechnology and bioengineering.

[38]  Viktor Menart,et al.  Production of Nonclassical Inclusion Bodies from Which Correctly Folded Protein Can Be Extracted , 2008, Biotechnology progress.

[39]  Bernd Nidetzky,et al.  Fusion to a pull‐down domain: a novel approach of producing Trigonopsis variabilisD‐amino acid oxidase as insoluble enzyme aggregates , 2007, Biotechnology and bioengineering.

[40]  X. Daura,et al.  AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides , 2007, BMC Bioinformatics.

[41]  Antonio Villaverde,et al.  Localization of Functional Polypeptides in Bacterial Inclusion Bodies , 2006, Applied and Environmental Microbiology.

[42]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[43]  Rainer Bischoff,et al.  Receptor-ligand binding assays: technologies and applications. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[44]  A. Villaverde,et al.  Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins , 2005, Microbial cell factories.

[45]  N. Maghsoudi,et al.  Process development for production of recombinant human interferon-γ expressed in Escherichia coli , 2004, Journal of Industrial Microbiology and Biotechnology.

[46]  I. Ivanov,et al.  A modified kynurenine bioassay for quantitative determination of human interferon-gamma. , 2002, Analytical biochemistry.

[47]  A. Meager,et al.  Biological assays for interferons. , 2002, Journal of immunological methods.

[48]  R. Kopito,et al.  Aggresomes, inclusion bodies and protein aggregation. , 2000, Trends in cell biology.

[49]  F. Winkler,et al.  Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex. , 2000, Structure.

[50]  G. de Prat-Gay,et al.  Folding of a pressure-denatured model protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[51]  F. Baneyx,et al.  Roles of the Escherichia coli Small Heat Shock Proteins IbpA and IbpB in Thermal Stress Management: Comparison with ClpA, ClpB, and HtpG In Vivo , 1998, Journal of bacteriology.

[52]  M. Montero,et al.  Production and characterization of human gamma interferon from Escherichia coli , 1990, Applied Microbiology and Biotechnology.

[53]  S. Dower,et al.  Properties of interleukin-1 and interferon-gamma receptors in B lymphoid cell line. , 1989, The Journal of biological chemistry.

[54]  G. Weber,et al.  Hysteresis and conformational drift of pressure-dissociated glyceraldehydephosphate dehydrogenase. , 1989, Biochemistry.

[55]  H. G. Drickamer,et al.  Plurality of pressure-denatured forms in chymotrypsinogen and lysozyme. , 1976, Biochemistry.

[56]  Christopher B Wilson,et al.  Regulation of interferon-gamma during innate and adaptive immune responses. , 2007, Advances in immunology.

[57]  C. Le Page,et al.  Interferon activation and innate immunity. , 2000, Reviews in immunogenetics.

[58]  A. Kossiakoff,et al.  The 2.0 A structure of bovine interferon-gamma; assessment of the structural differences between species. , 2000, Acta crystallographica. Section D, Biological crystallography.

[59]  J. Kuśba,et al.  Resolution of the conformational distribution and dynamics of a flexible molecule using frequency-domain fluorometry. , 1991, Biophysical chemistry.